Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Daiwa Keeps Hold Rating on TIGERMED w/ TP Raised to HKD45, Heightened Rev. Forecast
Recommend 3 Positive 3 Negative 3 |
||||
|
||||
|
TIGERMED (03347.HK) has issued a positive profit alert, expecting its revenue in 2025 to have grown by 1-16% YoY to RMB6.66-7.68 billion, resuming growth after an 11% decline in 2024, according to a report from Daiwa. The company's net profit is expected to have risen by 105-204% YoY to RMB830 million to RMB1.23 billion, while the recurring net profit will have dropped by 43-61% YoY to RMB330-490 million, mainly due to order cancellations, a decline in order prices, and escalated operational costs related to team expansion. Daiwa has lifted its 2026-27 revenue forecast for TIGERMED by 1-7%, but lowered its 2026-27 EPS forecast by 8-12%, given a reduction in gross margin and an increase in sales, administrative, and R&D expenses. TIGERMED's rating remains at Hold, and its target price has climbed from HKD38 to HKD45. AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
